France-based Atlab Pharma has reported positive data from a Phase II study of ATL101 (Lutetium-177 anti-PSMA antibody), conducted in patients with progressive metastatic castrate-resistant prostate cancer (mCRPC).
A statistically significant relationship between injected dose and antitumor activity was observed in the study, which demonstrated a favourable safety profile.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Atlab medical affairs head Professor Jean-François Chatal said the results signify the safety and the antitumor activity of ATL101 in mCRPC.
"ATL101 shows a steep dose effect on antitumor activity as expected from its radiotherapy mode of action and a potential in prolonging the life of patients with metastatic prostate cancer," Chatal said.
ATL101 was administered as a single intravenous injection at two radioactivity dose levels, 65mCi/m² or 70mCi/m², in two planned consecutive cohorts of the study enrolling 15 and 17 mCRPC patients respectively.
Later, a third expansion cohort of 15 patients was added at the 70mCi/m² dose.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to the data, all patients had failed up to four hormonal therapies and 55% had also failed at least one docetaxel containing chemotherapy regimen.
An increase from 13% of patients in cohort 1 to 47% in cohort 2 achieving PSA decline over 30% was observed.
Cohort 3 also showed a 30% PSA decline in 47% of patients.
The study observed treatment effect on the circulating tumour cells (CTC) count.
The study, in which the treatment was well-tolerated, showed significant improvement in median overall survival from 11.9 months in cohort 1 to 21.8 months in cohorts 2 and 3.
